Tremelimumab, another monoclonal antibody directly targets CTLA-4, is still in clinical development since it failed to demonstrate advantages in survival compared with standard chemotherapy in a phase III trial, even though tremelimumab generated durable tumor regression in phase I and II trials (57). Here, CTLA4 is linked to neoplasm.